Who Paid My Doc
Amanda Noska
Infectious Disease Minneapolis, MN Medical Doctor
NPI 1093031692 CMS profile 1369475
701 Park Ave, O1340, Minneapolis, MN 55415
General payments
$107
Research payments
$10,782
Ownership & investment interest
$0
Research they led as principal investigator
$462,378
Through program year 2024, Amanda Noska of Minneapolis, MN is reported in the CMS Open Payments database as having received $107 across 4 general payments and $10,782 in research payments paid to them. Separately, studies naming them as principal investigator received $462,378 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 88th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $59 | 1 | |
| 2024 | Research | $9,477 | 6 | |
| 2023 | Research | $23 | 1 | |
| 2022 | General | $16 | 1 | |
| 2022 | Research | $1,281 | 4 | |
| 2021 | General | $16 | 1 | |
| 2020 | General | $16 | 1 |
Beside peers
- Amanda Noska
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Amanda Noska were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Amanda Noska | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $190 | $60–$862 | $163 |
| 2020 | $16 | $124 | $32–$606 | $114 |
| 2021 | $16 | $148 | $38–$905 | $132 |
| 2022 | $16 | $166 | $50–$834 | $149 |
| 2023 | $0 | $171 | $57–$787 | $160 |
| 2024 | $59 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 72 drugsPart D claims
2,292
Drug cost
$1,672,687
Branded share of claims
36.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 95 | $366,610 | |
| Tivicay Dolutegravir Sodium | Brand | 139 | $343,256 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 91 | $335,203 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 84 | $246,985 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 54 | $123,221 | |
| Prezcobix Darunavir/Cobicistat | Brand | 38 | $93,931 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 23 | $92,235 | |
| Vemlidy Tenofovir Alafenamide | Brand | 12 | $17,708 | |
| Eliquis Apixaban | Brand | 18 | $10,534 | |
| Abacavir-Lamivudine Abacavir Sulfate/Lamivudine | Brand | 35 | $10,457 |
The 10 drugs with the highest cost, of 72 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$10,043
Medicare patients
47
Services billed
150
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Chronic kidney disease | 51% | |
| Depression | 51% | |
| Diabetes | 36% | |
| COPD | 34% | |
| Arthritis | 34% | |
| Ischemic heart disease | 28% | |
| Heart failure | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Infectious Disease in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.